Exelixis Newsroom

Brookline Capital Initiates Exelixis(EXEL.US) With Buy Rating, Announces Target Price $40

Moomoo NewsDec 23 05:34 ET · Ratings

Exelixis Initiated With a Buy at Brookline

TipRanksDec 23 05:25 ET

Exelixis Shares Decline After BMO Capital Downgrade

MT NewswiresDec 20 14:55 ET

BMO Capital Downgrades Exelixis(EXEL.US) to Hold Rating, Raises Target Price to $40

Moomoo NewsDec 20 13:31 ET · Ratings

Do Exelixis' (NASDAQ:EXEL) Earnings Warrant Your Attention?

Simply Wall StDec 20 10:11 ET

Express News | Exelixis Inc : BMO Cuts to Market Perform From Outperform

ReutersDec 20 07:05 ET

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Zacks Dec 19 12:30 ET

Peering Into Exelixis's Recent Short Interest

BenzingaDec 18 14:15 ET

Exelixis Risk/Reward Now 'More Balanced' With 2025 Catalysts Priced In, BofA Says

MT NewswiresDec 17 11:49 ET

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts

BenzingaDec 17 08:00 ET

This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

BenzingaDec 17 08:00 ET

Sairopa Reports Research Milestones Achieved in Partnership With Exelixis, Totalling $35 Million From Consecutive Clinical Milestone Payments in 2024

PR NewswireDec 17 08:00 ET

Exelixis Cut to Neutral From Buy by B of A Securities

Dow JonesDec 17 07:18 ET · Ratings

Exelixis Price Target Raised to $39.00/Share From $35.00 by B of A Securities

Dow JonesDec 17 07:18 ET · Ratings

Exelixis Analyst Ratings

BenzingaDec 17 07:06 ET · Ratings

BofA Securities Downgrades Exelixis(EXEL.US) to Hold Rating, Announces Target Price $39

Moomoo NewsDec 17 06:31 ET · Ratings

Exelixis Downgraded to Neutral From Buy at BofA

TipRanksDec 17 06:10 ET · Ratings

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

BenzingaDec 13 12:15 ET

Exelixis (EXEL) Is an Incredible Growth Stock: 3 Reasons Why

Zacks Dec 9 12:00 ET

AZN's Bladder Cancer SBLA for Imfinzi Gets FDA's Priority Tag

Zacks Dec 9 07:30 ET